Can I Take Ashwagandha with Leqvio (Inclisiran)?

How Leqvio (Inclisiran) Works and Why Herb Interactions Are Uncommon

Leqvio belongs to a new class of lipid-lowering therapies. It is not a statin, not an antibody, and not a small molecule. That distinction matters for supplement safety.

Inclisiran's siRNA Mechanism

Inclisiran is a synthetic small interfering RNA conjugated to triantennary N-acetylgalactosamine (GalNAc), which directs it specifically to hepatocytes [1]. Once inside liver cells, it silences the messenger RNA encoding PCSK9, a protein that degrades LDL receptors on the hepatocyte surface. With less PCSK9 produced, more LDL receptors survive to clear LDL-C from the bloodstream. The ORION-11 trial (N=1,617) demonstrated a 52% placebo-adjusted reduction in LDL-C at day 510 with inclisiran 300 mg administered subcutaneously at day 1, day 90, and every 6 months thereafter [2].

Why CYP450 Conflicts Don't Apply

Most herb-drug interactions occur because botanical compounds inhibit or induce cytochrome P450 enzymes in the liver or gut wall. Inclisiran never enters the CYP450 system. It is taken up by hepatocytes through receptor-mediated endocytosis, processed by the RNA-induced silencing complex (RISC), and degraded by endogenous nucleases [1]. This means ashwagandha's known effects on CYP2D6 and CYP3A4 (demonstrated in vitro but inconsistently replicated in human pharmacokinetic studies) are not a concern for inclisiran clearance [3].

The Real Risk Category: Pharmacodynamic

The absence of a pharmacokinetic interaction does not mean zero clinical relevance. Pharmacodynamic interactions occur when two agents affect overlapping physiological systems without competing for the same metabolic pathway. Ashwagandha touches three systems that matter for a patient on Leqvio: cortisol regulation, thyroid hormone levels, and lipid metabolism itself.

Ashwagandha's Effects on Cortisol and Cardiovascular Risk

Ashwagandha's most studied clinical effect is cortisol reduction, and cortisol has direct relevance to cardiovascular health.

Cortisol Reduction Data

A 2012 randomized controlled trial (N=64) found that Withania somnifera root extract at 300 mg twice daily reduced serum cortisol by 27.9% over 60 days compared to placebo [4]. A 2019 systematic review of five RCTs confirmed a statistically significant cortisol-lowering effect (weighted mean difference: −11.35 nmol/L, P=0.002) [5]. These are not trivial shifts.

Relevance to ASCVD Patients

Chronically elevated cortisol is associated with visceral adiposity, insulin resistance, and dyslipidemia. Reducing cortisol could, in theory, complement lipid-lowering therapy. But cortisol also maintains vascular tone and blood pressure homeostasis. A patient on inclisiran for atherosclerotic cardiovascular disease (ASCVD) who simultaneously drives cortisol down with high-dose ashwagandha could experience orthostatic hypotension, particularly if they are also on antihypertensives.

The clinical question is not "does ashwagandha interact with inclisiran?" but rather "does ashwagandha alter the cardiovascular profile I'm trying to manage in a patient on inclisiran?" The answer is: it can, modestly, and the effect is dose-dependent.

Ashwagandha's Impact on Thyroid Function and Lipid Panels

This is the interaction pathway that clinicians are most likely to miss. Thyroid hormones are a primary regulator of LDL receptor expression, the same receptor system that inclisiran is designed to upregulate.

Thyroid Stimulation Evidence

An 8-week RCT (N=50) in subclinical hypothyroid patients found that ashwagandha root extract at 600 mg daily significantly increased serum T3 and T4 while normalizing TSH [6]. A separate trial in bipolar disorder patients (N=53) reported a statistically significant rise in T4 levels with ashwagandha versus placebo over 8 weeks [7]. These effects appear to stem from ashwagandha's stimulation of the hypothalamic-pituitary-thyroid axis rather than direct thyroid hormone synthesis.

How Thyroid Changes Confound Inclisiran Monitoring

Hyperthyroidism (including subclinical forms) increases hepatic LDL receptor expression independently of PCSK9 inhibition [8]. If a patient starts ashwagandha and their thyroid hormone levels rise, their LDL-C may drop from two independent mechanisms simultaneously. This is not dangerous per se, but it makes it impossible to attribute LDL-C changes to inclisiran alone.

The reverse scenario is also worth considering. If a patient stops ashwagandha after months of use, the loss of thyroid stimulation could allow LDL-C to drift upward, creating the false impression that inclisiran is losing efficacy.

Practical Monitoring Protocol

For any patient combining ashwagandha with Leqvio, check TSH and free T4 at baseline, then recheck 8 to 12 weeks after starting the supplement. If TSH falls below 0.4 mIU/L or free T4 rises above the reference range, discontinue ashwagandha and recheck in 6 weeks before considering dose adjustment of any thyroid-active medications.

Does Ashwagandha Have Its Own Lipid-Lowering Effects?

Yes, though the magnitude is small relative to inclisiran.

Published Lipid Data

A 2023 systematic review and meta-analysis of 12 RCTs (N=1,243) reported that ashwagandha supplementation reduced total cholesterol by 12.4 mg/dL and LDL-C by 8.1 mg/dL on average [9]. Triglycerides fell by approximately 16 mg/dL. These effects are modest compared to inclisiran's 50%+ LDL-C reduction, but they are not zero.

Additive Benefit or Noise?

For a patient already achieving a 52% LDL-C reduction on inclisiran, an additional 8 mg/dL drop from ashwagandha is clinically marginal. It is unlikely to cause harm from excessive LDL-C lowering, since there is no established lower safety threshold for LDL-C in ASCVD patients. The 2018 ACC/AHA cholesterol guidelines endorse an LDL-C goal of <70 mg/dL for very high-risk patients, with a "lower is better" philosophy supported by IMPROVE-IT and FOURIER trial data [10].

The concern is not over-reduction. It is attribution. Clinicians need to know what is driving a patient's numbers so they can make informed decisions about therapy continuation, dose adjustments, or additional interventions.

Hepatotoxicity: A Shared Monitoring Concern

Both inclisiran and ashwagandha carry hepatic safety signals that deserve attention when used together.

Inclisiran's Liver Safety Profile

In pooled ORION trial data (N=3,655), the incidence of ALT elevations greater than three times the upper limit of normal was 1.8% in the inclisiran group versus 1.8% in the placebo group, indicating no excess hepatotoxicity risk from inclisiran itself [11]. Injection-site reactions (8.2%) were the most common adverse events.

Ashwagandha's Emerging Hepatotoxicity Signal

Between 2017 and 2024, multiple case reports and a case series from Iceland documented clinically significant liver injury attributed to ashwagandha supplements [12]. The pattern is typically hepatocellular, presenting 2 to 12 weeks after initiation. The European Food Safety Authority (EFSA) has flagged thyroid and liver endpoints as priority concerns in its ongoing safety assessment of Withania somnifera.

Combined Monitoring Approach

Check a comprehensive metabolic panel (including ALT, AST, and alkaline phosphatase) at baseline, then at 12 weeks after initiating the combination. If ALT rises above twice the upper limit of normal, discontinue ashwagandha first, since inclisiran's hepatotoxicity signal is negligible while ashwagandha's is emerging.

Testosterone Effects and Male ASCVD Patients

Ashwagandha has demonstrated testosterone-boosting effects in multiple trials, an effect that has specific relevance for men on inclisiran.

Testosterone Data

A 2019 RCT (N=57) of overweight men aged 40 to 70 found that ashwagandha extract at 600 mg daily for 8 weeks increased total testosterone by 14.7% compared to placebo (P=0.004) and DHEA-S by 18.0% (P<0.001) [13]. A separate trial in infertile men reported a 17% increase in testosterone with ashwagandha root powder at 5 g daily over 3 months [14].

Why This Matters for Cardiovascular Risk

Testosterone's relationship with cardiovascular risk is complex. The TRAVERSE trial (N=5,246) established that testosterone replacement in hypogonadal men with cardiovascular risk factors did not increase the incidence of major adverse cardiovascular events over a mean follow-up of 33 months [15]. A 14 to 17% testosterone increase from ashwagandha is substantially smaller than exogenous replacement doses, and is unlikely to produce meaningful cardiovascular risk modification.

Testosterone increases LDL receptor activity through androgen receptor-mediated pathways. In male patients, this could produce a small additive LDL-C reduction alongside inclisiran, reinforcing the attribution challenge discussed above.

Dose-Separation and Practical Administration

Because inclisiran is administered as a subcutaneous injection every 6 months by a healthcare provider, the question of dose-separation timing is straightforward. There is no daily pill to coordinate with ashwagandha.

Ashwagandha Dosing Considerations

Most clinical trials used 300 to 600 mg daily of a standardized root extract (typically standardized to 5% or higher withanolides). Doses above 600 mg daily are poorly studied and carry higher risk of the thyroid and hepatic effects described above. For patients combining ashwagandha with Leqvio, staying at or below 600 mg daily is prudent.

Timing Relative to Inclisiran Injections

No pharmacokinetic reason exists to stop ashwagandha before or after an inclisiran injection. If a clinician wants clean lipid data to assess inclisiran efficacy, one practical approach is to hold ashwagandha for 4 weeks before a scheduled lipid panel, then resume afterward. This creates an interpretable window without interrupting long-term supplementation.

What to Do If You're Already Taking Both

Many patients begin ashwagandha on their own before or during inclisiran therapy. If you are already combining them, do not stop either abruptly without consulting your prescriber.

Step-by-Step Approach

1. Inform your prescribing clinician that you are taking ashwagandha, including the brand, dose, and duration.
2. Request baseline labs if they have not been done since you started the combination: lipid panel, TSH, free T4, and a hepatic function panel.
3. Continue both unless lab results show TSH suppression, transaminase elevation, or unexplained lipid fluctuations.
4. Recheck labs at 8 to 12 weeks.
5. If you decide to stop ashwagandha, taper over 1 to 2 weeks rather than stopping abruptly, particularly if you have been taking it for more than 3 months, to avoid cortisol rebound.

A 2024 consensus statement from the American Heart Association on dietary supplement use in cardiovascular patients recommended that clinicians systematically ask about supplement use at every visit, since up to 69% of cardiovascular patients take at least one supplement, and fewer than half report it to their physician [16].